A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

April 20, 2023

Study Completion Date

November 1, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

SPH6516 tablets

SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle

Trial Locations (2)

Sun Yat-sen University Cancer Center, Guangzhou

Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai

All Listed Sponsors

lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY